THERAPEUTIC EVALUATION OF KAISORA GUGGULU AND MADHUSNUHI RASAYANA IN VATARAKTA (GOUT)
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 55
- 试验地点
- 1
- 主要终点
- MEAN PERCENTAGE DECREASE IN SERUM URIC ACID LEVEL FROM THE BASELINE TO THE END OF THE STUDY.
研究概览
简要总结
Kaishora Guggulu and Madhusnuhi Rasayana (AFI:Part-I/API(formulation):Part-II ) will taken for the trail because both the drugs are indicated for disease Vatarakta. The drugs like Guggulu,Guduchi,Gandhaka,Madhusnuhi etc are the ingredients of theses two formulations.
It is evidendance that Guduchi is the drug of choice for Vatarakta and is a magnificent Rasayana, Rakta Dosha and Daha Nasaka (Nighantu ratna kara, Raja nighantu). Madhusnuhi has the quality of Vatavyadhi Nashana (Bhavaprakasha), Rasayana, Rakta Dosha Nashana and is indicated in Dhatu Kshaya (Nighantu Ratnakara). Guggulu is Rasayana and Vata Dosha Nasaka (Bhava Prakasha).The use of Kaishora Guggulu is a optimum selection for the management of Vatarakta (AYU, oct-Dec-2010,Vol-31,issue-4). Smilax china L.(Madhusnuhi) exhibits anti-hyperuricemic and nephroprotective activity in hyperuricemic animals (Journal of Ethnopharmacol, May 2011,135(2); pg. 399-405)
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 25.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •FULFILLING THE DIAGNOSTIC CRITERIA AS RECOMMENDED BY THE AMERICAN COLLEGE OF RHEUMATOLOGY (1977).
排除标准
- •PATIENTS WITH TRAUMA, FRACTURE, HEART DISEASE, MALIGNANCY, HYPO-HYPER THYROIDISM, DRUG ABUSERS, PREGNANT, LACTATING WOMEN AND ANY OTHER CONDITION WHICH THE PRINCIPAL INVESTIGATOR THINKS MAY JEOPARDIZE THE STUDY.
结局指标
主要结局
MEAN PERCENTAGE DECREASE IN SERUM URIC ACID LEVEL FROM THE BASELINE TO THE END OF THE STUDY.
时间窗: Total Study Period: 24 months | Pre-trial preparatory period: | ï¶Recruitment of staff/Literature survey/ Screening | of patients/Procurement of medicine etc. : 3 months | ï¶Washout Period (if required): 02 weeks | Recruitment patients/follow ups/ data recording: 18 months | Data analysis/report preparation/ submission: 03 months | Treatment Period: 12 weeks | Follow-Up Period: 02 weeks
次要结局
- IMPROVEMENT IN SF-36 HEALTH SURVEY SCORE, PATIENTS GLOBAL ASSESSMENT PAIN VISUAL ANALOGUE SCALE.(Total Study Period: 24 months)